Possible Mortality Imbalance For Shionogi's Cefiderocol On US FDA Panel Agenda

 
• By Michael Cipriano

Although cefiderocol demonstrated safety and efficacy in a pivotal trial for complicated urinary tract infections, there was a mortality imbalance between the study drug and comparator arms in a separate descriptive trial; the US FDA is unsure whether the imbalance was a "chance finding."

X-ray image of bladder, Showing cystitis or lower urinary tract infection
Shionogi's cUTI Candidate Cefiderocol Will Head To A US FDA Advisory Committee.

More from US FDA Performance Tracker

More from Regulatory Trackers